GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,536.00p
   
  • Change Today:
    -38.50p
  • 52 Week High: 1,812.50
  • 52 Week Low: 1,382.00
  • Currency: UK Pounds
  • Shares Issued: 4,145.06m
  • Volume: 15,431,722
  • Market Cap: £63,668m
  • RiskGrade: 129
  • Beta: 0.02

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

1 Day Chart (20-09-2024)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.9% 0.0%
Div Cover n/a 2.6
Op Mrgn n/a 27.4%
ROCE n/a  
Latest F'cast
P/E 39.6 9.7
PEG n/a 3.9
Pr/Revenue 9.6 2.0
Pr/Book 5.3  
Latest F'cast
Revenue n/a 330.2%
PBT 7.7% 540.8%
EPS n/a 2.5%
DPS n/a 301.3%

GSK Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 33,754.00 6,221.00 123.90p 17.9 4.5 +4% 80.00p 3.6%
31-Dec-20 34,099.00 6,968.00 115.90p 14.5 n/a -6% 80.00p 4.8%
31-Dec-21 24,696.00 3,599.00 90.56p 22.2 n/a -22% 80.00p 4.0%
31-Dec-22 29,324.00 5,628.00 139.70p 10.3 0.2 +54% 44.00p 3.1%
31-Dec-23 30,328.00 6,064.00 155.10p 9.4 0.9 +11% 42.00p 2.9%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

GSK Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-24 31,678.14 8,682.20 158.96p 9.7 3.9 +2% 60.19p 0.0%
31-Dec-25 33,484.64 9,664.43 175.43p 8.8 0.8 +10% 63.82p 0.0%
31-Dec-26 35,405.21 10,753.85 194.78p 7.9 0.7 +11% 67.94p 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

GSK Company Announcements

Statement: Zantac (ranitidine) litigation 18-Sep-2024 13:20 RNS
Japan Filing Acceptance: Blenrep Multiple Myeloma 17-Sep-2024 07:00 RNS
China Breakthrough Therapy Designation for Blenrep 13-Sep-2024 07:00 RNS

GSK ShareCast News

GSK settles two Zantac cases in California 18-Sep-2024 ShareCast
Japan to review GSK's Blenrep drug application 17-Sep-2024 ShareCast
London close: Stocks finish firmer in subdued tr... 13-Sep-2024 ShareCast

GSK Top Newspaper Links

GSK to close Cumbrian factory after 75 years 16-Sep-2024 Times
GlaxoSmithKline scraps sale of old drugs 05-Dec-2014 Telegraph
Glaxo sharpens axe to save £1bn as insurers and ... 01-Dec-2014 The Independent

Latest GSK Director Deals

Traded Action Notifier PriceAmountValue
10-Sep-24 Transfer From Julie Brown 0.000p 8 £0.00
10-Sep-24 Buy Julie Brown 1,669.28p 8 £133.54
10-Sep-24 Transfer From Emma Walmsley 0.000p 8 £0.00

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

GSK Market Data

Currency UK Pounds
Share Price 1,536.00p
Change Today -38.50p
% Change -2.45 %
52 Week High 1,812.50
52 Week Low 1,382.00
Volume 15,431,722
Shares Issued 4,145.06m
Market Cap £63,668m
Beta 0.02
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
53.68% below the market average53.68% below the market average53.68% below the market average53.68% below the market average53.68% below the market average
6.12% above the sector average6.12% above the sector average6.12% above the sector average6.12% above the sector average6.12% above the sector average
Price Trend
7.57% above the market average7.57% above the market average7.57% above the market average7.57% above the market average7.57% above the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average
Income
23.38% above the market average23.38% above the market average23.38% above the market average23.38% above the market average23.38% above the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average
Growth
6.21% below the market average6.21% below the market average6.21% below the market average6.21% below the market average6.21% below the market average
21.21% above the sector average21.21% above the sector average21.21% above the sector average21.21% above the sector average21.21% above the sector average

What The Brokers Say

Strong Buy 8
Buy 4
Neutral 10
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q2 Q1
Ex-Div 15-Aug-24 16-May-24
Paid 10-Oct-24 11-Jul-24
Amount 15.00p 15.00p

Trades for 20-Sep-2024

Time Volume / Share Price
16:47 77,620 @ 1,536.00p
16:42 1,274 @ 1,536.00p
16:42 43,210 @ 1,536.00p
16:42 167 @ 1,536.00p
16:35 6,000 @ 1,536.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page